GSA Capital Partners’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-22,944
| Closed | -$777K | – | 2086 |
|
|
2025
Q4 | $777K | Buy |
22,944
+12,386
| +117% | +$385K | 0.07% | 516 |
|
|
2025
Q3 | $272K | Sell |
10,558
-1,586
| -13% | -$20.8K | 0.02% | 1256 |
|
|
2025
Q2 | $97K | Buy |
+12,144
| New | +$92.6K | 0.01% | 1619 |
|
|
2024
Q3 | – | Sell |
-4,582
| Closed | -$112K | – | 1937 |
|
|
2024
Q2 | $112K | Buy |
+4,582
| New | +$212K | 0.01% | 1520 |
|
|
2024
Q1 | – | Sell |
-2,554
| Closed | -$508K | – | 1903 |
|
|
2023
Q4 | $508K | Sell |
2,554
-1,286
| -33% | -$159K | 0.04% | 791 |
|
|
2023
Q3 | $510K | Sell |
3,840
-553
| -13% | -$90.3K | 0.04% | 783 |
|
|
2023
Q2 | $657K | Buy |
4,393
+598
| +16% | +$93.1K | 0.07% | 570 |
|
|
2023
Q1 | $557K | Buy |
+3,795
| New | +$768K | 0.06% | 642 |
|
|
2022
Q4 | – | Sell |
-4,736
| Closed | -$912K | – | 1813 |
|
|
2022
Q3 | $912K | Buy |
4,736
+3,346
| +241% | +$633K | 0.12% | 203 |
|
|
2022
Q2 | $203K | Sell |
1,390
-974
| -41% | -$130K | 0.03% | 1061 |
|
|
2022
Q1 | $416K | Buy |
2,364
+1,266
| +115% | +$239K | 0.06% | 666 |
|
|
2021
Q4 | $323K | Sell |
1,098
-3,080
| -74% | -$823K | 0.04% | 881 |
|
|
2021
Q3 | $1.04M | Buy |
+4,178
| New | +$1.1M | 0.11% | 299 |
|
GSA Capital Partners's RAPT Position: Q1 2026 in Review
GSA Capital Partners sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 22,944 shares — an estimated $777K sold.
GSA Capital Partners first reported a position in RAPT in Q3 2021 and held it in 13 quarters. The position peaked at $1.04M in Q3 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- GSA Capital Partners reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- GSA Capital Partners sold 22,944 RAPT Therapeutics shares in Q1 2026, an estimated $777K.
- GSA Capital Partners first reported a position in RAPT Therapeutics in Q3 2021 and held it in 13 quarters.
- GSA Capital Partners's RAPT Therapeutics position peaked at $1.04M in Q3 2021.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.